Preclinical studies accounted for a significant reduction in mTOR/p70S6K signaling in the PFC of patients experiencing depression [94], where, ketamine (noncompetitive NMDA receptor antagonist) imply rapid anti-depressant effect by modulating mTOR activation [95]. This evidence concerns the gene MTOR and depressive symptom measurement.